EFFECTS OF HALF-DOSE PHOTODYNAMIC THERAPY ON CHRONIC CENTRAL SEROUS CHORIORETINOPATHY WITH OR WITHOUT MACULAR NEOVASCULARIZATION ASSESSED USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY.
Journal
Retina (Philadelphia, Pa.)
ISSN: 1539-2864
Titre abrégé: Retina
Pays: United States
ID NLM: 8309919
Informations de publication
Date de publication:
01 12 2022
01 12 2022
Historique:
received:
13
04
2022
accepted:
05
08
2022
entrez:
17
11
2022
pubmed:
18
11
2022
medline:
22
11
2022
Statut:
ppublish
Résumé
To assess the effects of half-dose photodynamic therapy on subretinal fluid and macular neovascularization (MNV) using optical coherence tomography angiography in patients with chronic central serous chorioretinopathy. Clinical information on 168 patients (168 eyes) with chronic central serous chorioretinopathy obtained before and 6 months after treatment with half-dose photodynamic therapy was retrospectively analyzed. Patients were categorized into a success (145 eyes) or failure (23 eyes) group based on the absence or presence of subretinal fluid, respectively, and clinical data were compared between them. Macular neovascularization was studied in 147 cases with available optical coherence tomography angiography images. P < 0.05 indicated statistical significance. The success group showed a younger patient age, better posttreatment best-corrected visual acuity, and thicker pretreatment central choroidal thickness (all, P < 0.047) than did the failure group. Regarding MNV analysis, nine, eight, and 130 eyes had definite, possible, and no MNV, respectively, at baseline; among them, 100.0%, 75.0%, and 2.3%, respectively, had MNV at 6 months posttreatment. Patients with definite MNV at baseline were less likely to show successful subretinal fluid resolution. Although half-dose photodynamic therapy is generally effective for the treatment of chronic central serous chorioretinopathy, coexisting MNV may compromise the outcome; thus, optical coherence tomography angiography-based assessment of chronic central serous chorioretinopathy is important.
Identifiants
pubmed: 36394889
doi: 10.1097/IAE.0000000000003604
pii: 00006982-202212000-00014
doi:
Substances chimiques
Photosensitizing Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2346-2353Références
Cheung CMG, Lee WK, Koizumi H, et al. Pachychoroid disease. Eye (Lond) 2019;33:14–33.
Yanagi Y. Pachychoroid disease: a new perspective on exudative maculopathy. Jpn J Ophthalmol 2020;64:323–337.
Imamura Y, Fujiwara T, Spaide RF. Fundus autofluorescence and visual acuity in central serous chorioretinopathy. Ophthalmology 2011;118:700–705.
Fung AT, Yannuzzi LA, Freund KB. Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration. Retina 2012;32:1829–1837.
Azzolini C, Cattaneo J, Premoli L, et al. The morphology of choroidal neovascularization in chronic central serous chorioretinopathy presenting with flat, irregular pigment epithelium detachment. Int Ophthalmol 2021;41:2109–2116.
Guo J, Tang W, Liu W, et al. Clinical features of flat irregular pigment epithelial detachment associated with choroidal neovascularization in chronic central serous chorioretinopathy. Retina 2021;41:199–207.
Demirel S, Yanık Ö, Özcan G, et al. A comparative study on the choroidal vascularity index and the determination of cut-off values in the pachychoroid spectrum diseases. Jpn J Ophthalmol 2021;65:482–491.
Hage R, Mrejen S, Krivosic V, et al. Flat irregular retinal pigment epithelium detachments in chronic central serous chorioretinopathy and choroidal neovascularization. Am J Ophthalmol 2015;159:890–903 e893.
Ferrara D, Mohler KJ, Waheed N, et al. En face enhanced-depth swept-source optical coherence tomography features of chronic central serous chorioretinopathy. Ophthalmology 2014;121:719–726.
Dansingani KK, Balaratnasingam C, Klufas MA, et al. Optical coherence tomography angiography of shallow irregular pigment epithelial detachments in Pachychoroid spectrum disease. Am J Ophthalmol 2015;160:1243–1254.e2.
Bousquet E, Bonnin S, Mrejen S, et al. Optical coherence tomography angiography of flat irregular pigment epithelium detachment in chronic central serous chorioretinopathy. Retina 2018;38:629–638.
Hwang H, Kim JY, Kim KT, et al. Flat irregular pigment epithelium detachment in central serous chorioretinopathy: a form of pachychoroid neovasculopathy? Retina 2020;40:1724–1733.
Erikitola OC, Crosby-Nwaobi R, Lotery AJ, Sivaprasad S. Photodynamic therapy for central serous chorioretinopathy. Eye (Lond) 2014;28:944–957.
Türkçüoğlu P, Ilhan N, Kurt J, et al. The protective role of Visudyne eyeglass against VEGF synthesis after photodynamic therapy with verteporfin. Acta Ophthalmol 2009;87:871–874.
Lai TY, Chan WM, Li H, et al. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol 2006;90:869–874.
Chan WM, Lai TY, Lai RY, et al. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina 2008;28:85–93.
Fujita K, Imamura Y, Shinoda K, et al. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology 2015;122:555–561.
Haga F, Maruko R, Sato C, et al. Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: a 3-year follow-up study. PLOS ONE 2017;12:e0181479.
Oiwa K, Kataoka K, Maruko R, et al. Half-dose photodynamic therapy for chronic central serous chorioretinopathy evaluated by focal macular electroretinograms. Jpn J Ophthalmol 2017;61:260–266.
Terao N, Koizumi H, Kojima K, et al. Association of upregulated angiogenic cytokines with choroidal abnormalities in chronic central serous chorioretinopathy. Invest Ophthalmol Vis Sci 2018;59:5924–5931.
Wu JS, Chen SN. Optical coherence tomography angiography for diagnosis of choroidal neovascularization in chronic central serous chorioretinopathy after photodynamic therapy. Sci Rep:sci Rep 90402019;9:9040.
Hu YC, Chen YL, Chen YC, Chen SN. 3-year follow-up of half-dose verteporfin photodynamic therapy for central serous chorioretinopathy with OCT-angiography detected choroidal neovascularization. Sci Rep Sci Rep 2021;11:13286.
Chen YC, Chen SN. Three-year follow-up of choroidal neovascularisation in eyes of chronic central serous chorioretinopathy. Br J Ophthalmol 2020;104:1561–1566.
Kitajima Y, Maruyama-Inoue M, Ito A, et al. One-year outcome of combination therapy with intravitreal anti-vascular endothelial growth factor and photodynamic therapy in patients with pachychoroid neovasculopathy. Graefes Arch Clin Exp Ophthalmol 2020;258:1279–1285.
Matsumoto H, Mukai R, Kikuchi Y, et al. One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions. Jpn J Ophthalmol 2020;64:203–209.
Miki A, Kusuhara S, Otsuji T, et al. Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy. PLOS ONE 2021;16:e0248760.